natgillin/translations-raw huggingface dataset:
The method of any one of the preceding claims, wherein the method is combined with one or more methods for estimating the impact on the perception quality of a digital video signal by other impairments than compression and/or transmission, wherein the combination is preferably performed using at least a linear function and/or at least a multiplicative function of the methods to be combined. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se postupak kombinira s jednim ili više postupaka procjenjivanja utjecaja na kvalitetu percepcije digitalnog video signala oštećenjima koja nisu uzrokovana kompresijom i/ili prijenosom, gdje se kombiniranje po mogućnosti provodi uz upotrebu u najmanju ruku linearne funkcije i/ili u najmanju ruku funkcije množenja u postupcima koje treba kombinirati.
The method of any one of the preceding claims, wherein the method is combined with one or more other methods for estimating the perception quality of a digital video by compression and/or transmission, wherein the combination is preferably performed using at least a linear function and/or at least a multiplicative function of the methods to be combined. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se postupak kombinira s jednim ili više drugih postupaka procjenjivanja kvalitete percepcije digitalnog videa kompresijom i/ili prijenosom, gdje se kombiniranje po mogućnosti provodi uz upotrebu u najmanju ruku linearne funkcije i/ili u najmanju ruku funkcije množenja u postupcima koje treba kombinirati.
Apparatus for estimating the perception quality of a digital video signal, the apparatus comprising: 
Uređaj za procjenjivanje kvalitete percepcije digitalnog video signala, gdje se navedeni uređaj sastoji od:
a means configured for extracting information from a video bit stream being captured prior to decoding; 
naprave konfigurirane za izvlačenje informacija iz struje video bitova koji je uhvaćen prije dekodiranja;
a quality estimator configured for estimating the perception quality Qv of the video signal; the apparatus being characterised in that each of the impact estimator(s) is configured for estimating the quality impact due to an impairment factor by means of an impairment function taking as input a set of content-dependent parameters q computed from a set of GOP/scene-complexity parameters, wherein the GOP/scene-complexity parameters are derivable from packet-header information and thus available in case of encrypted video bit streams; 
gdje je uređaj naznačen time što je svaki od jednog ili više procjenjivača utjecaja konfiguriran za procjenjivanje kvalitete utjecaja faktora oštećenja uz pomoć funkcije oštećenja, gdje se kao ulaz uzima skup parametara ovisnih o sadržaju q izračunatih iz skupa GOP/parametara složenosti scene, gdje se GOP/parametre složenosti scene može izvesti iz informacija o zaglavlju paketa i stoga dostupnih u slučaju enkriptiranih struja video bitova;
wherein for estimating at least one of the impairment factors, preferably the quality impact due to compression artifacts, an impact function fIF is used that depends on a content-dependent parameter q1 being computed from the reciprocal of the weighted mean of the GOP/scene-complexity parameter EPMATHMARKEREP over the scenes sc multiplied by a coefficient; and wherein each scene sc has a weight of wsc × Nsc with Nsc being the number of GOPs per scene and wsc being a weight factor, wherein for the scenes having the lowest EPMATHMARKEREP value: wsc is set to a value greater than 1, for example wsc =16, and for all other scenes: wsc is set equal to 1. 
gdje se kod procjenjivanja najmanje jednog od faktora oštećenja, po mogućnosti utjecaja kvalitete zbog artefakata kompresije, upotrijebi funkcija utjecaja fIF koja ovisi o parametru ovisnom o sadržaju q1 izračunatom iz recipročne vrijednosti ponderirane srednje vrijednosti GOP/parametra složenosti scene [image] preko scena sc pomnoženih s koeficijentom; i gdje svaka scena sc ima težinu wsC 3 NsC, gdje je NsC broj GOP-ova po sceni, a wsC je faktor težine, gdje za scene s najnižom vrijednošću [image]: wsC je podešen na vrijednost veću od 1, primjerice wsC =16, a za sve druge scene: wsC je podešen da bude jednak 1.
The synthetic NRP compound of any one of claims 1 to 3 or the pharmaceutical composition of claim 4 for use in a method of treating a neurological disorder in a mammal comprising administering to the mammal a pharmaceutically effective amount of the synthetic NRP compound or pharmaceutical composition. 
Sintetički spoj NRP prema bilo kojem od zahtjeva 1 do 3, ili farmaceutski sastav prema zahtjevu 4, naznačen time, da se upotrebljava u postupku liječenja neuroloških poremećaja kod sisavaca, koji obuhvaća primjenu farmaceutski učinkovite količine sintetičkog spoja NRP ili farmaceutskog sastava na sisavcu.
The synthetic NRP compound or pharmaceutical composition of claim 6 where the neurological disorder is amyotrophic lateral sclerosis, neurotoxin injury, oxidative injury, multiple sclerosis, peripheral neuropathy, hypoxia/ischemia, traumatic brain injury, or coronary artery bypass graft surgery, preferably diabetic peripheral neuropathy. 
Sintetički spoj NRP ili farmaceutski sastav prema zahtjevu 6, naznačen time, da je neurološki poremećaj sljedeći: amiotrofička lateralna skleroza, neurotoksična ozljeda, oksidativna lezija, multipla skleroza, periferna neuropatija, hipoksija/ishemija, traumatska ozljeda mozga ili transplatacija premosnice koronarne arterije, poželjno dijabetička periferna neuropatija.
A method for determining the efficacy of adalimumab for the treatment of ankylosing spondylitis (AS) in a subject having AS, said method comprising determining a post-treatment level of type II collagen C-telopeptide (CTX-II) in a sample(s) from the subject having AS wherein a decrease in the level of CTX-II of at least 9% relative to a known standard level of CTX-II based on a subject(s) having AS indicates that adalimumab is efficacious for the treatment of AS in the subject. 
Postupak za određivanje učinkovitosti adalimumaba za liječenje ankilozantnog spondilitisa (AS)) kod subjekta koji boluje od AS, spomenuti postupak uključuje određivanje razine tipa II kolagen C-telopeptida (CTX-II) poslije liječenja u uzorku (ili uzorcima) od subjekta sa AS, naznačen time, da smanjenje razine CTX -II od najmanje 9 % u odnosu na poznatu standardnu razinu CTX-II kod subjekta (ili subjekata) sa AS pokazuje da je adalimumab učinkovit u liječenju AS kod subjekta.
The method of claim 1, wherein the post-treatment level of CTX-II in the sample(s) obtained from the subject is at least about 9% decrease relative to the known standard level of CTX-II based on a subject(s) having AS. 
Postupak prema zahtjevu 1, naznačen time, da je razina CTX -II nakon liječenja u uzorku (ili uzorcima) dobivenim od subjekta smanjena najmanje oko 9 % u odnosu na poznatu standardnu razinu CTX -II kod subjekta(ili subjekata) koji ima AS.
The method of claim 1, wherein the post-treatment level of MMP3 in the sample(s) obtained from the subject is at least about a 8% decrease relative to the known standard level of MMP3 based on a subject(s) having AS. 
Postupak prema zahtjevu 1, naznačen time, da je razina MMP3 nakon liječenja u uzorku (ili uzorcima) dobivenim od subjekta smanjena najmanje oko 8 % u odnosu na poznate standardnu razinu MMP3 kod subjekta(ili subjekata) koji ima AS.
The method of any one of claims 1-8, further comprising comparing the subject's C-reactive protein (CRP) level with a known standard CRP level associated with the AS; and assessing whether the subject's CRP level is higher than the known standard CRP level, wherein a lower CRP level relative to the known standard level of CRP indicates efficacy of treatment. 
Postupak prema bilo kojem od zahtjeva 1-8, naznačen time, da nadalje obuhvaća uspoređivanje razine subjektovog C-reaktivnog proteina (CRP) s poznatom standardnom razinom CRP povezanom s AS; i procjenu da li je razina CRP subjekta viša od poznate standardne razine CRP, pri čemu niži CRP razinu u odnosu na poznatu standardnu razinu CRP ukazuje na učinkovitost liječenja.
A chemical system for thermally treating an oil reservoir by initiating a chemical reaction in a pay zone of said oil reservoir, wherein said chemical system comprises at least the following two compositions: 
Kemijski sustav za termalnu obradu naftnog ležišta iniciranjem kemijske reakcije u zoni iskoristivosti navedenog naftnog ležišta, naznačen time, da navedeni kemijski sustav sadrži barem dva sljedeća sastava:
a thermal gas emitting composition (TGEC) being an aqueous solution or suspension comprising at least one compound selected from the group consisting of hydrazine nitrate, 1,1-di C2-6 alkyl hydrazine nitrates and 1,2-di C2-6 alkyl hydrazine nitrates, such as 1,1-dimethyl hydrazine nitrate or 1,2-dimethyl hydrazine nitrate, guanidine nitrate, formamide nitric acid adduct, acetamide nitric acid adduct, acetonitrile nitric acid adduct, urea nitric acid adduct, ammonium nitrate, potassium nitrate, sodium nitrate, calcium nitrate, mono, di and tri C1-5 alkyl amine nitrates, mono, di and tri C1-5 alkanol amine nitrates, C2-6 alkylene diamine mono and dinitrates and poly C1-5 alkylene polyamine polynitrates; and a reaction initiator stabilizer (RIS) being a liquid solution or suspension and comprising at least one compound selected from the group consisting of: 
sastav koji emitira termalni plin (Thermal gas emitting composition – TGEC), koji je vodena otopina ili suspenzija, što sadrži barem jedan spoj odabran iz skupine koja se sastoji od hidrazin nitrata, 1,1-di C2-6 alkil hidrazin nitrata i 1,2-di-C2-6 alkil hidrazin nitrata, kao što su 1,1-dimetil hidrazin nitrat ili 1,2-dimetil hidrazin nitrat, gvanidin nitrat, adicioni spoj formamid dušična kiselina, adicioni spoj acetamid dušična kiselina, adicioni spoj acetonitril dušična kiselina, adicioni spoj urea dušična kiselina, amonijakov nitrat, kalijev nitrat, natrijev nitrat, kalcijev nitrat, mono di i tri C1-5 alkil amin nitrati, mono di i tri C1-5 alkanol amin nitrati, C2-6 alkilen diamin mono i dinitrati ipoli C1-5 alkilen poliamin polinitrati; i stabilizator-inicijator reakcije (Reaction initiator stabilizer - RIS), koji je tekuća otopina ili suspenzija i sadrži barem jedan spoj odabran iz skupine koja se sastoji od:
The chemical system according to claim 1, wherein the TGEC is an aqueous solution or suspension comprising at least one compound selected from the group consisting of hydrazine nitrate, 1,1-di C2-6 alkyl hydrazine nitrates and 1,2-di C2-6 alkyl hydrazine nitrates, such as 1,1-dimethyl hydrazine nitrate or 1,2-dimethyl hydrazine nitrate, guanidine nitrate, formamide nitric acid adduct, acetamide nitric acid adduct, urea nitric acid adduct and acetonitrile nitric acid adduct. 
Kemijski sustav prema patentnom zahtjevu 1, naznačen time, da je TGEC vodena otopina ili suspenzija koja sadrži baren jedan spoj odabran iz skupine koja se sastoji od hidrazin nitrata, 1,1-di C2-6 alkil hidrazin nitrata i 1,2-di C2-6 alkil hidrazin nitrata, kao što su 1,1-dimetil hidrazin nitrat ili 1,2-dimetil hidrazin nitrat, gvanidin nitrat, adicioni spoj formamid dušična kiselina, adicioni spoj acetamid dušična kiselina, adicioni spoj urea dušična kiselina i adicioni spoj acetonitril dušična kiselina.
The chemical system according to claim 1 or 2, wherein the TGEC is the reaction product of reacting nitric acid with a respective amino compound. 
Kemijski sustav prema patentnom zahtjevu 1 ili 2, naznačen time, da TGEC jest produkt reakcije dušične kiseline s odnosnim amino spojem.
The chemical system according to any of claims 1 to 4, wherein the RIS is a solution or suspension in an appropriate solvent. 
Kemijski sustav prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time, da RIS jest otopina ili suspenzija u odgovarajućem otapalu.
The chemical system according to claim 5, wherein the solvent for the RIS is water or an organic solvent selected from the group consisting of petrol, ligroin, white spirit, kerosene and naphtha. 
Kemijski sustav prema patentnom zahtjevu 5, naznačen time, da otapalo za RIS jest voda ili organsko otapalo odabrano iz skupine koja se sastoji od benzina, ligroina, terpentina, kerozina i nafte.
A method of thermally treating an oil reservoir by initiating a chemical reaction in a pay zone of said oil reservoir, by using a chemical system comprising at least the following two compositions: 
Postupak termalne obrade naftnog ležišta iniciranjem kemijske reakcije u zoni iskoristivosti navedenog naftnog ležišta, naznačen time, da koristi kemijski sustav, koji sadrži barem dva sljedeća sastava:
aluminum or aluminum alloys with magnesium, wherein said thermal gas emitting composition (TGEC) and said reaction initiator stabilizer (RIS) are separately introduced into said oil reservoir and are contacted in the pay zone of said oil reservoir to initiate a chemical reaction producing heat and gases, and wherein the TGEC is continuously introduced into the oil reservoir and the RIS is introduced simultaneously and in a continuous or intermittent way into the oil reservoir. 
aluminija ili aluminijevih legura s magnezijem, u čemu se navedeni sastav koji emitira termalni plin (TGEC) i navedeni stabilizator –inicijator reakcije (RIS) odvojeno uvode u navedeno naftno ležište i dovode se u kontakt u zoni iskoristivosti navedenog naftnog ležišta da iniciraju kemijsku reakciju proizvodeći toplinu i plinove, i u čemu se TGEC kontinuirano uvodi u naftno ležište, a RIS se u naftno ležište uvodi istovremeno i na kontinuirani ili isprekidani način.
The method according to claims 8 or 9, wherein the TGEC is an aqueous solution or suspension comprising at least one compound selected from the group consisting of hydrazine nitrate, 1,1-di C2-6 alkyl hydrazine nitrates and 1,2-di C2-6 alkyl hydrazine nitrates, such as 1,1-dimethyl hydrazine nitrate or 1,2-dimethyl hydrazine nitrate, guanidine nitrate, formamide nitric acid adduct, acetamide nitric acid adduct, urea nitric acid adduct and acetonitrile nitric acid adduct. 
Postupak prema patentnom zahtjevu 8 ili 9, naznačen time, da je TGEC vodena otopina ili suspenzija koja sadrži baren jedan spoj odabran iz skupine koja se sastoji od hidrazin nitrata, 1,1-di C2-6 alkil hidrazin nitrata i 1,2-di C2-6 alkil hidrazin nitrata, kao što je 1,1-dimetil hidrazin nitrat ili 1,2-dimetil hidrazin nitrat, gvanidin nitrat, adicioni spoj formamid dušična kiselina, adicioni spoj acetamid dušična kiselina, adicioni spoj urea dušična kiselina i adicioni spoj acetonitril dušična kiselina.
The method according to claims 8 to 10, wherein the TGEC is the reaction product of reacting nitric acid with a respective amino compound. 
Postupak prema patentnim zahtjevima 8 do 10, naznačen time, da TGEC jest produkt reakcije dušične kiseline s odnosnim amino spojem.
The method according to claim 13, wherein the solvent for the RIS is water or an organic solvent selected from the group consisting of petrol, ligroin, white spirit, kerosene and naphtha. 
Postupak prema patentnom zahtjevu 13, naznačen time, da otapalo za RTS jest voda ili organsko otapalo odabrano iz skupine koja se sastoji od benzina, ligroina, terpentina, kerozina i nafte.
introducing the TGEC into the oil well so that it contacts said granules kept in the reaction chamber for initiating and maintaining a thermochemical reaction producing heat and gases; 
uvođenje TGEC u naftnu bušotinu, tako da dođe u kontakt s navedenim granulama koje se drže u reakcijskoj komori za iniciranje i održavanje termokemijske reakcije koja proizvodi toplinu i plinove;
passing the produced hot gases into the pay zone of the oil reservoir; 
prolaz proizvedenih vrelih plinova u zonu iskoristivosti naftnog ležišta;
shifting the thermochemical reaction into the pay zone of the oil reservoir by allowing said granules to enter into the pay zone; and contacting the granules in the pay zone with the TGEC introduced into the oil well. 
pomicanje termokemijske reakcije u zonu iskoristivosti naftnog ležišta omogućujući navedenim granulama da uđu u zonu iskoristivosti; i dovođenje u kontakt granula u zoni iskoristivosti s TGEC, uvedenim u naftnu bušotinu.
The method according to claim 18, wherein said reaction chamber is located in or adjacent to the pay zone of the oil reservoir. 
Postupak prema patentnom zahtjevu18, naznačen time, da je navedena reakcijska komora smještena u zoni iskoristivosti naftnog ležišta ili neposredno uz nju.
The method according to claim 18 or 19, wherein urea nitric acid adduct is used as the TGEC. 
Postupak prema patentnom zahtjevu 18 ili 19, naznačen time, da se adicioni spoj urea dušična kiselina koristi kao TGEC.
introducing granules of aluminum or an aluminum/magnesium alloy as the RIS into an oil well of said oil reservoir and keeping said granules in a first reaction chamber located in the oil well; 
uvođenje granula aluminija ili aluminijeve/magnezijeve legure kao RIS-a u naftnu bušotinu navedenog naftnog ležišta i držanje navedenih granula u prvoj reakcijskoj komori lociranoj u naftnoj bušotini;
introducing a first TGEC into the oil well so that it contacts said granules kept in said first reaction chamber for initiating and maintaining a thermochemical reaction producing thermal energy and heating up the walls of said first reaction chamber; 
uvođenje prvog TGEC u naftnu bušotinu tako da dođe u kontakt s navedenim granulama koje se drže u navedenoj prvoj reakcijskoj komori za iniciranje i održavanje termokemijske reakcije proizvodeći termalnu energiju i zagrijavajući stijene navedene prve reakcijske komore;
introducing a second TGEC into the oil well such that it comes in contact with the heated walls of said first reaction chamber and is ignited; 
uvođenje drugog TGEC u naftnu bušotinu tako da dođe u kontakt sa zagrijanim stijenama navedene prve reakcijske komore i zapali se;
passing the ignited TGEC to a second reaction chamber where the TGEC reacts under production of heat and gases; and passing the produced hot gases into the pay zone of the oil reservoir. 
prolaz zapaljenog TGEC u drugu reakcijsku komoru, gdje TGEC reagira pod proizvodnjom topline i plinova; i prolaz proizvedenih vrelih plinova u zonu iskoristivosti naftnog ležišta.
A process for manufacturing a forged roll, the process comprising the steps of: 
Postupak proizvodnje kovanog valjka, postupak se sastoji od:
Providing a steel composition according to the steel composition mentioned in claim 1 
Priprava sastava čelika prema sastavu čelika navedenom pod točkom 1.
Manufacturing an ingot maintaining a solidification rate higher than 15°C/min both in the working layer and also in the core of the ingot in the solidification interval; 
Proizvodnja ingota koja sadrži stupanj soldifikacije viši od 15°C kako u radnom sloju tako i u jezgri u intervalu soldifikacije. kovanje ingota u valjak
The process of any of claims 21-24, wherein the ingot is manufactured maintaining a pre-selected solidification rate in an electro-slag refining furnace (ESR) technique process by controlling the ampere current supply according to a predetermined function of the solidification rate. 
Postupak prema bilo kojem od zahtjeva iz točke 21-24, pri čemu je ingot proizveden sadržavajući predodabran stupanj soldifikacije u tehnici elektro-šljaka prerađivačke topionice (ESR) upravljajući dovod ampera struja prema predodređenom stupnju soldifikacije.
The process of any of claims 21-25, wherein the step of forging the ingot to a roll comprises the steps of: 
Postupak prema bilo kojem od zahtjeva iz točke 21-25, pri čemu se postupak kovanja ingota u valjak sastoji od sljedećih koraka
The process of any of claims 21-27, wherein the step of tempering the roll comprises the steps of: 
Postupak prema bilo kojem od zahtjeva iz točke 21-27, pri čemu se korak učvršćivanja valjka sastoji od sljedećih koraka:
Air cooling the roll between the heating steps. The process of any of claims 21-28, further comprising machining the roll to texturing a white layer comprising eutectic carbides. 
Postupak prema bilo kojem od zahtjeva iz točke 21-28, nadalje se sastoji u obradi valjka do strukturiranja bijelog sloja, koji obuhvaća eutektične karbide.
The compound of claim 4, wherein R10 is hetCyc1, -(1-3Calkyl)hetCyc1a or hetCyc2, wherein hetCyc1 and hetCyc1a are optionally substituted with one or more R9 groups. 
Spoj prema zahtjevu 4, naznačen time da R10 je hetCyc1, -(1-3C alkil)hetCycla ili hetCyc2, gdje su hetCyc1 i hetCycla po izboru supstituirani s jednom ili više R9 skupina.
The compound of claim 13, wherein R12 is hetCyc3 optionally substituted with one or more R9 groups. 
Spoj prema zahtjevu 13, naznačen time da R12 je hetCyc3 po izboru supstituiran s jednom ili više R9 skupina.
A compound as defined in claim 25, wherein the inflammatory or autoimmune disease is multiple sclerosis, lupus or inflammatory bowel disease. 
Spoj kako je definiran u zahtjevu 25, naznačen time da upalna ili autoimuna bolest jest multipla skleroza, lupus ili upalna bolest crijeva.
for a compound of Formula I wherein A is NR11R12, coupling a corresponding compound having the formula II wherein L1 represents a leaving atom or group, with a compound having the formula HNR11R12, using a palladium (II) catalyst and a ligand in the presence of a base; or 
za spoj formule I gdje A je NR11R12, spajanje odgovarajućeg spoja formule II [image] gdje L1 predstavlja odlazeći atom ili skupinu, sa spojem formule HNR11R12, uporabom paladij (II) katalizatora i liganda u prisutnosti baze; ili
for a compound of Formula I wherein A is OR10 coupling a corresponding compound having the Formula V with a compound having the formula HO-R10 in the presence of a coupling agent and triphenylphosphine in a suitable solvent; or 
za spoj Formule I gdje A je OR10, spajanje odgovarajućeg spoja Formule V [image] sa spojem formule HO-R10 u prisutnosti sredstva za spajanje i trifenilfosfina u prikladnom otapalu; ili
for a compound of Formula I wherein B is (CH2)NRbRc, reacting a corresponding compound having the Formula VI with hydrazine; or 
za spoj Formule I gdje B je (CH2)NRbRc, reakciju odgovarajućeg spoja Formule VI [image] s hidrazinom; ili
for a compound of Formula I where B is ORa, reacting a corresponding compound having the Formula VII with a compound of the formula Ra-L2, wherein L2 represents a leaving atom or group, in the presence of a base; and removing any protecting group or groups and, if desired, forming a salt. A compound of claim 1, selected from: 
za spoj Formule I gdje B je ORa, reakciju odgovarajućeg spoja Formule VII [image] sa spojem formule Ra-L2, gdje L2 predstavlja odlazeći atom ili skupinu, u prisutnosti baze; i uklanjanje bilo koje zaštitne skupine ili skupina i, po želji, formiranje soli.
working up the reaction mixture produced in step (i) by sequential treatment of said reaction mixture with LiOH in water followed by HCl in isopropyl acetate to liberate the free acid from the acetate form of the product; 
daljnji rad s reakcijskom smjesom dobivenom u koraku (i) tako da se ta reakcijska smjesa dalje obradi s LiOH u vodi nakon čega slijedi HCl u izopropil acetatu radi oslobađanja slobodne kiseline iz acetatnog oblika produkta;
treating the free acid produced in step (ii) with a tertiary amine in isopropylacetate to precipitate the tertiary amine salt of Formula Ic, 
obrada slobodne kiseline proizvedene u koraku (ii) s tercijarnim aminom u izopropilacetatu da se istaloži sol tercijarnog amina Formule Ic,
when the salt compound selected in Step (iv) is a compound of Formula Id', oxidizing the compound Ic produced in Step (iv) to yield the compound of Formula I. 
ako je spoj soli izabran u koraku (iv) spoj Formule Id’, oksidacija spoja Ic dobivenog u koraku (iv) da se dobije spoj Formule I.
A process according to claim 1 characterized in that step (iv) is carried out in a polar organic solvent selected from ethyl acetate, acetonitrile, dimethylformamide, dimethylacetamide, and N-methyl-2-pyrrolidinone (NMP), and mixtures of two or more thereof. 
Postupak prema zahtjevu 1 naznačen time što se korak (iv) provodi u polarnom organskom otapalu koje se izabire između etil acetata, acetonitrila, dimetilformamida, dimetilacetamida, i N-metil-2-pirolidinona (NMP), te mješavina dvaju ili tri od njih.